Abstract
Methimazole (MMI) is a widely used antithyroid drug, which inhibits thyroid hormone synthesis by interfering with the activity of thyroid peroxidase (Cooper, 2005). However, MMI is sometimes associated with cutaneous adverse drug reactions (cADRs), varying from urticaria and maculopapular eruption to severe reactions such as drug-induced hypersensitivity syndrome (Burch and Cooper, 2015; Ozaki et al., 2005). MMI-induced cADRs cannot always be predicted and sometimes could be life-threatening, requiring or prolonging hospitalization, impeding proper treatment, and increasing treatment costs considerably.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
